Kathleen Burlew, Caravella McCuistian & José Szapocznik
doi : 10.1186/s13722-021-00256-4
Addiction Science & Clinical Practice volume 16, Article number: 50 (2021)
Opioid use and opioid-related overdose continue to rise among racial/ethnic minorities. Social determinants of health negatively impact these communities, possibly resulting in poorer treatment outcomes. Research is needed to investigate how to overcome the disproportionate and deleterious impact of social determinants of health on treatment entry, retention, drug use and related outcomes among racial/ethnic minorities. The current commentary provides recommendations that may help researchers respond more effectively to reducing health disparities in substance use treatment.
Allison M. Gustavson, Marie E. Kenny, Jennifer P. Wisdom, Hope A. Salameh, Princess E. Ackland, Adam J. Gordon & Hildi J. Hagedorn
doi : 10.1186/s13722-021-00259-1
Addiction Science & Clinical Practice volume 16, Article number: 51 (2021)
The Veterans Health Administration (VHA) is invested in expanding access to medication treatment for opioid use disorder (MOUD) to save lives. Access varies across VHA facilities and, thus, requires implementation strategies to promote system-wide adoption of MOUD. We conducted a 12-month study employing external facilitation that targeted MOUD treatment among low-adopting VHA facilities. In this study, we sought to evaluate the patterns of perceived barriers over 1 year of external implementation facilitation using the integrated Promoting Action on Research Implementation in Health Services (i-PARIHS) framework.
Judith I. Tsui, Michael P. Barry, Elizabeth J. Austin, Elsa W. Sweek, Elyse Tung, Ryan N. Hansen, Michael Ninburg, John D. Scott, Sara N. Glick & Emily C. Williams
doi : 10.1186/s13722-021-00260-8
Addiction Science & Clinical Practice volume 16, Article number: 52 (2021)
The advent of direct-acting antivirals (DAAs)—a form of hepatitis C (HCV) treatment associated with shorter treatment course and greater efficacy—offers an unprecedented opportunity to eliminate HCV, but only if care delivery systems are developed to extend treatment to people who inject drugs (PWID). To support the design of a community-pharmacy program, we explored perspectives of PWID with chronic HCV with regard to barriers, motivators, preferences, and prior experiences related to HCV treatment and pharmacists.
Kirsten Marchand, Corinne Tallon, Christina Katan, Jill Fairbank, Oonagh Fogarty, Katrina Marie Pellatt, Roxanne Turuba, Steve Mathias & Skye Barbic
doi : 10.1186/s13722-021-00261-7
Addiction Science & Clinical Practice volume 16, Article number: 53 (2021)
Opioid use is one of the most critical public health issues as highly potent opioids contribute to rising rates of accidental opioid-related toxicity deaths. This crisis has affected people from all age groups, including youth (ages 15–24) who are in a critical developmental period where the stakes of opioid use are especially high. Efforts to reduce the significant harms of opioid use have focused on the expansion of evidence-based treatments, including medications for opioid use disorder (e.g. buprenorphine). While these treatments are unequivocally life saving, recent evidence suggests that they may not align with youths’ needs. Accordingly, the ‘Improving Treatment Together’ (ITT) project has been designed with the aim to improve youths’ opioid treatment service experiences and outcomes by co-developing, implementing, and measuring youth-centred opioid use treatment service innovations. This manuscript describes the protocol for this multi-phase project.
Lindsay R. Meredith, Erica N. Grodin, Mitchell P. Karno, Amanda K. Montoya, James MacKillop, Aaron C. Lim & Lara A. Ray
doi : 10.1186/s13722-021-00262-6
Addiction Science & Clinical Practice volume 16, Article number: 54 (2021)
Findings have been mixed as to whether brief intervention (BI) is appropriate and effective for individuals with more severe alcohol use problems. Motivation to change drinking has been supported as a mechanism of behavior change for BI. This exploratory study examined aspects of motivation as mechanisms of clinical response to BI and alcohol problem severity as a moderator of treatment effects.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟